|
|
(31 intermediate revisions by 5 users not shown) |
Line 13: |
Line 13: |
| <link rel="stylesheet" type="text/css" href="https://2015.igem.org/Template:Peking/Blue/new?action=raw&ctype=text/css " title="blue" media="screen" /> | | <link rel="stylesheet" type="text/css" href="https://2015.igem.org/Template:Peking/Blue/new?action=raw&ctype=text/css " title="blue" media="screen" /> |
| <style type="text/css">/*get rid of the annoying iGEM style*/ | | <style type="text/css">/*get rid of the annoying iGEM style*/ |
| + | #top_menu_inside, #top_menu_inside:before, #top_menu_inside:after { -webkit-box-sizing: content-box; -moz-box-sizing: border-box; box-sizing: content-box;} |
| + | #top_menu_under{font-size: 12px;} |
| + | #top_menu_14{font-size: 12px; height:18px} |
| + | #top_menu_inside li{font-size: 12px;} |
| + | #user_item{font-size: 12px;} |
| #content{padding:0;border:0;width:100%;} | | #content{padding:0;border:0;width:100%;} |
| .firstHeading{visibility:hidden;} | | .firstHeading{visibility:hidden;} |
Line 18: |
Line 23: |
| .carousel-control.left, .carousel-control.right{background-image: none} | | .carousel-control.left, .carousel-control.right{background-image: none} |
| /* to style the sidebar*/ | | /* to style the sidebar*/ |
− | h3{ border-bottom: 1px solid #00afd1;}
| + | |
| @media (min-width:1024px){ | | @media (min-width:1024px){ |
| #sidebar1{position:relative;top:120px;max-width:200px;} | | #sidebar1{position:relative;top:120px;max-width:200px;} |
Line 30: |
Line 35: |
| } | | } |
| .back-to-top{z-index:9999;} | | .back-to-top{z-index:9999;} |
− | | + | |
| + | ul.dropdown{margin-left: 0px; margin-top: 0px;} |
| + | .classic-title span { |
| + | position: absolute; |
| + | margin-top: -30px; |
| + | border-bottom-color: #00afd1; |
| + | } |
| + | .page-banner{ |
| + | background-color:#e0e0e0;margin-top:1%;margin-bottom:20px;padding:20px;padding-top:40px; |
| + | } |
| </style> | | </style> |
| </head> | | </head> |
Line 53: |
Line 67: |
| </div> | | </div> |
| <div class="navbar-collapse collapse" style="padding-top:5px;padding-bottom:0"> | | <div class="navbar-collapse collapse" style="padding-top:5px;padding-bottom:0"> |
− | <!-- Start Navigation List -->
| + | <!-- Start Navigation List --> |
− | <ul class="nav navbar-nav navbar-right " style="padding-bottom:15px;height:88px;padding-top:10px">
| + | <ul class="nav navbar-nav navbar-right " style="padding-bottom:15px;padding-top:10px"> |
| <li> | | <li> |
| <a href="https://2015.igem.org/Team:Peking/JudgingCriteria">Achievements</a> | | <a href="https://2015.igem.org/Team:Peking/JudgingCriteria">Achievements</a> |
Line 71: |
Line 85: |
| <li><a href="https://2015.igem.org/Team:Peking/Design">Overview</a> | | <li><a href="https://2015.igem.org/Team:Peking/Design">Overview</a> |
| </li> | | </li> |
− | <li><a href="#">CRIPSR</a> | + | <li><a href="https://2015.igem.org/Team:Peking/Design/PC_Reporter">Paired <span style="text-transform:lowercase">d</span>Cas9 Reporter</a> |
| </li> | | </li> |
− | <li><a href="#">Isothermal PCR</a> | + | <li><a href="https://2015.igem.org/Team:Peking/Design/Isothermal">Iso-<span style="text-transform:lowercase">t</span>hermal Amplification</a> |
| + | <li><a href="https://2015.igem.org/Team:Peking/Device">Hardware</a> |
| </li> | | </li> |
− | <li><a href="#">B. subtillis</a> | + | <li><a href="https://2015.igem.org/Team:Peking/Design/Speculation">Speculation</a> |
− | </li>
| + | |
− | <li><a href="#">Device</a>
| + | |
| </li> | | </li> |
| </ul> | | </ul> |
| </li> | | </li> |
| <li> | | <li> |
− | <a href="https://2015.igem.org/Team:Peking/Modeling">Modelling</a> | + | <a href="https://2015.igem.org/Team:Peking/Modeling">Modeling</a> |
| <ul class="dropdown"> | | <ul class="dropdown"> |
− | <li><a href="#">Link 1</a> | + | <li><a href="https://2015.igem.org/Team:Peking/Modeling">Array Design</a> |
| </li> | | </li> |
− | <li><a href="#">Link 2</a> | + | <li><a href="https://2015.igem.org/Team:Peking/Modeling/Analysis">Analysis algorithm</a> |
| </li> | | </li> |
| </ul> | | </ul> |
Line 95: |
Line 108: |
| <li><a href="https://2015.igem.org/Team:Peking/Practices">Overview</a> | | <li><a href="https://2015.igem.org/Team:Peking/Practices">Overview</a> |
| </li> | | </li> |
− | <li><a class="active" href="#">TB Facts</a> | + | <li><a class="active" href="https://2015.igem.org/Team:Peking/Practices/Background">Facts about TB</a> |
| </li> | | </li> |
| <li><a href="https://2015.igem.org/Team:Peking/Practices/Consultation">Consultation and Interview</a> | | <li><a href="https://2015.igem.org/Team:Peking/Practices/Consultation">Consultation and Interview</a> |
Line 130: |
Line 143: |
| | | |
| <!-- Start Page Banner --> | | <!-- Start Page Banner --> |
− | <div class="page-banner" style="background-color:#e0e0e0;margin-top:1%;margin-bottom:20px;padding:20px"> | + | <div class="page-banner"> |
| <div class="container"> | | <div class="container"> |
| <div class="row"> | | <div class="row"> |
| <div class="col-md-6"> | | <div class="col-md-6"> |
− | <h2 style="font-size:20px; margin-bottom:5px; padding-bottom:0"><b>Practices</b></h2> | + | <h2 style="font-size:20px; margin-bottom:5px; padding-bottom:0">P<span style="text-transform:lowercase">ractices</span></h2> |
| <p style="margin-top:0px;font-size:14px">Study how our work affects the world, and how the world affects our work.</p> | | <p style="margin-top:0px;font-size:14px">Study how our work affects the world, and how the world affects our work.</p> |
| </div> | | </div> |
Line 157: |
Line 170: |
| <!-- Categories Widget --> | | <!-- Categories Widget --> |
| <div id="sidebar1"class="widget widget-categories" > | | <div id="sidebar1"class="widget widget-categories" > |
− | <h4 style="font-size:18px">Practices<span class="head-line"></span></h4> | + | <h4 style="font-size:18px">P<span style="text-transform:lowercase">ractices</span><span class="head-line"></span></h4> |
| <ul> | | <ul> |
| <li> | | <li> |
Line 172: |
Line 185: |
| </li> | | </li> |
| <li> | | <li> |
− | <a href="https://2015.igem.org/Team:Peking/Practices/Outreach">Ethic and Economic Issue</a> | + | <a href="https://2015.igem.org/Team:Peking/Practices/Outreach">Ethic and Economic Issues</a> |
| </li> | | </li> |
| </ul> | | </ul> |
| </div> | | </div> |
| <div id="sidebar2"class="widget widget-categories"> | | <div id="sidebar2"class="widget widget-categories"> |
− | <h4 style="font-size:18px">Practices<span class="head-line"></span></h4> | + | <h4 style="font-size:18px">P<span style="text-transform:lowercase">ractices</span><span class="head-line"></span></h4> |
| <ul> | | <ul> |
| <li> | | <li> |
Line 192: |
Line 205: |
| </li> | | </li> |
| <li> | | <li> |
− | <a href="https://2015.igem.org/Team:Peking/Practices/Outreach">Ethic and Economic Issue</a> | + | <a href="https://2015.igem.org/Team:Peking/Practices/Outreach">Ethic and Economic Issues</a> |
| </li> | | </li> |
| </ul> | | </ul> |
Line 199: |
Line 212: |
| <!--End sidebar--> | | <!--End sidebar--> |
| <!-- Page Content --> | | <!-- Page Content --> |
− | <div class="col-md-9 page-content"> | + | <div class="col-md-9 page-content" style="text-align:justify;"> |
| <div id="practices"> | | <div id="practices"> |
| <!-- Classic Heading --> | | <!-- Classic Heading --> |
Line 208: |
Line 221: |
| </p> | | </p> |
| </div> | | </div> |
− | <h3 class="classic-title" style="margin-top:50px;"><span>Part Ⅰ White plague is staging a comeback</span></h3> | + | <h3 class="classic-title" style="margin-top:50px; "><span style="border-bottom-color:#00afd1">White plague is staging a comeback</span></h3> |
| <div style="margin-top:30px; margin-bottom:0"> | | <div style="margin-top:30px; margin-bottom:0"> |
| <p>“Pale complexion, gaunt trunk, and a fit of acute coughing…” There are no lack of descriptions like these in the novels and dramas of the 19th century. What caused these clinical signs in those years was the pulmonary tuberculosis (TB), also called “the white plague”. In the 19th century, there were millions of people died of this fulminating infectious disease. It became curable and preventable since the applying of antibiotics and BCG in the 20th century. Nevertheless, WHO has warned the whole world that the white plague is staging a comeback; we should never get slack at the prevention and control of tuberculosis. | | <p>“Pale complexion, gaunt trunk, and a fit of acute coughing…” There are no lack of descriptions like these in the novels and dramas of the 19th century. What caused these clinical signs in those years was the pulmonary tuberculosis (TB), also called “the white plague”. In the 19th century, there were millions of people died of this fulminating infectious disease. It became curable and preventable since the applying of antibiotics and BCG in the 20th century. Nevertheless, WHO has warned the whole world that the white plague is staging a comeback; we should never get slack at the prevention and control of tuberculosis. |
| </p> | | </p> |
− | <div class="col-md-12" id="picture of Mycobacterium tuberculosis"> | + | <div class="col-md-12" id="picture of <i>Mycobacterium tuberculosis</i>"> |
| <img src="https://static.igem.org/mediawiki/2015/c/c8/Peking-Practice-Background-pic1.jpeg"> | | <img src="https://static.igem.org/mediawiki/2015/c/c8/Peking-Practice-Background-pic1.jpeg"> |
− | <p class="text-center"><small><b>Chest X-ray of a pulmonary TB patient (left) <sup>[1]</sup> and a healthy person (right) <sup>[2]</sup>.</b><br/><b>(a)</b>Diffusion and random distribution of numerous miliary nodules and fibrous-cavities with thick walls in a pulmonary TB patient. M= miliary pattern. Arrow indicates cavities at the right upper lobe.<b>(b)</b>Normal structures in chest. L= left collarbone.</small></p> | + | <p><small><b>Figure 1.Chest X-ray of a pulmonary TB patient (left) [1]and a healthy person (right) [2].</b><b>(a)</b>Diffusion and random distribution of numerous miliary nodules and fibrous-cavities with thick walls in a pulmonary TB patient. M= miliary pattern. Arrow indicates cavities at the right upper lobe.<b>(b)</b>Normal structures in chest. L= left collarbone.</small></p> |
| </div> | | </div> |
| <p> | | <p> |
− | In 1882, a German scientist named Robert Koch announced his discovery of Mycobacterium tuberculosis. Pulmonary tuberculosis is exactly a kind of chronic wasting disease with high contagiosity, which is caused by the invasion of Mycobacterium tuberculosis into the lungs. As the bacteria grow in the lung tissue, the patients may develop chronic fibro-cavitary pulmonary tuberculosis or miliary tuberculosis. If the former, you can find huge cavities with thick wall in the patients’ lungs (Figure 1a, Figure 2). The latter means that the bacteria have destroyed the lung tissue and result in the diffuse and random distribution of numerous miliary nodules in both lungs (Figure 1a, Figure 2). As for the mode of transmission, over 90% of pulmonary tuberculosis cases are spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected. | + | In 1882, a German scientist named Robert Koch announced his discovery of <i>Mycobacterium tuberculosis</i>. Pulmonary tuberculosis is exactly a kind of chronic wasting disease with high contagiosity, which is caused by the invasion of <i>Mycobacterium tuberculosis</i> into the lungs. As the bacteria grow in the lung tissue, the patients may develop chronic fibro-cavitary pulmonary tuberculosis or miliary tuberculosis. If the former, you can find huge cavities with thick wall in the patients’ lungs (Figure 1a, Figure 2). The latter means that the bacteria have destroyed the lung tissue and result in the diffuse and random distribution of numerous miliary nodules in both lungs (Figure 1a, Figure 2). As for the mode of transmission, over 90% of pulmonary tuberculosis cases are spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected. |
| </p> | | </p> |
| <div class="col-md-12" id="picture of Mycobacterium tuberculosis"> | | <div class="col-md-12" id="picture of Mycobacterium tuberculosis"> |
Line 227: |
Line 240: |
| <div class="col-md-3"></div> | | <div class="col-md-3"></div> |
| </div> | | </div> |
− | <p class="text-center"><small><b>Figure 2. Cavitating pulmonary TB - gross pathology image [3].</b><br/>There is prominent scarring and cavitation, predominantly affecting the apical aspect of the right lung<b>(A)</b>, along with nodules of calcification at the left upper lobe<b>(B)</b></small></p> | + | <p><small><b>Figure 2. Cavitating pulmonary TB - gross pathology image [3].</b>There is prominent scarring and cavitation, predominantly affecting the apical aspect of the right lung<b>(A)</b>, along with nodules of calcification at the left upper lobe<b>(B)</b></small></p> |
| </div> | | </div> |
| <p> The appearance of chemotherapeutic drugs and BCG vaccine can be marked as the milestone in the antituberculous history, which has saved millions of lives. However, this kind of stubborn communicable disease has launched a new round of assault on human beings. According to the report from WHO, there is a trend that TB has become a more and more threatening disease all over the world. In 1995, 3 million people died of TB, much more than the death toll in 1900, making it a horrible year with the largest number of deaths. | | <p> The appearance of chemotherapeutic drugs and BCG vaccine can be marked as the milestone in the antituberculous history, which has saved millions of lives. However, this kind of stubborn communicable disease has launched a new round of assault on human beings. According to the report from WHO, there is a trend that TB has become a more and more threatening disease all over the world. In 1995, 3 million people died of TB, much more than the death toll in 1900, making it a horrible year with the largest number of deaths. |
Line 234: |
Line 247: |
| </div> | | </div> |
| | | |
− | <h3 class="classic-title" style="margin-top:50px"><span>Part Ⅱ Epidemic status of TB in the world</span></h3> | + | <h3 class="classic-title" style="margin-top:50px"><span>Epidemic status of TB in the world</span></h3> |
| <div> | | <div> |
| <div> | | <div> |
− | <img class="col-md-12" src="https://static.igem.org/mediawiki/2015/e/ef/Peking-Practice-Background-pic3.jpeg">
| + | <div class="row"> |
| + | <div class="col-md-2"></div> |
| + | <div class="col-md-8"> |
| + | <img src="https://static.igem.org/mediawiki/2015/e/ef/Peking-Practice-Background-pic3.jpeg"> |
| + | </div> |
| + | <div class="col-md-2"></div> |
| + | </div> |
| <p class="text-center"><small><b>Figure 3. Top six countries with the largest number of new TB cases in 2013.</b></small></p> | | <p class="text-center"><small><b>Figure 3. Top six countries with the largest number of new TB cases in 2013.</b></small></p> |
| </div> | | </div> |
| <p> | | <p> |
− | TB now is considered as a severe communicable disease in the world, ranking as the 2nd leading cause of death among various infectious diseases, just after the human immunodeficiency virus (HIV). According to the Global Tuberculosis Report 2014, it was estimated that there were 9 million people infected with Mycobacterium tuberculosis, more than a half in the area of Southeast Asia and Western Pacific. In details, 56% of the new cases occurred in Asia, and 29% in the African region. The six countries that stand out as having the largest number of incident cases in 2013 are India, China, Nigeria, Pakistan, Indonesia and South Africa (Figure 3). India and China alone accounted for 24% and 11% of the global cases respectively [4]. With most TB cases occurring in Asia and Africa, the regional imbalance of TB control is increasingly serious (Figure 4). The lowest rates are found predominantly in high-income countries including most countries in Western Europe, Canada, the United States of America. Poverty in low-income countries indicate that most common people in the society cannot afford the high medical fees of TB diagnosis. This current situation urges the whole world to develop a cheaper detection method for <i>Mycobacterium tuberculosis.</i></p> | + | TB now is considered as a severe communicable disease in the world, ranking as the 2nd leading cause of death among various infectious diseases, just after the human immunodeficiency virus (HIV). According to the Global Tuberculosis Report 2014, it was estimated that there were 9 million people infected with <i>Mycobacterium tuberculosis</i>, more than a half in the area of Southeast Asia and Western Pacific. In details, 56% of the new cases occurred in Asia, and 29% in the African region. The six countries that stand out as having the largest number of incident cases in 2013 are India, China, Nigeria, Pakistan, Indonesia and South Africa (Figure 3). India and China alone accounted for 24% and 11% of the global cases respectively [4]. With most TB cases occurring in Asia and Africa, the regional imbalance of TB control is increasingly serious (Figure 4). The lowest rates are found predominantly in high-income countries including most countries in Western Europe, Canada, the United States of America. Poverty in low-income countries indicate that most common people in the society cannot afford the high medical fees of TB diagnosis. This current situation urges the whole world to develop a cheaper detection method for <i>Mycobacterium tuberculosis.</i></p> |
− | <div class="col-md-12">
| + | <div class="row"> |
| + | <div class="col-md-2"></div> |
| + | <div class="col-md-8"> |
| <img src="https://static.igem.org/mediawiki/2015/d/d4/Peking-Practice-Background-pic4.png" style="max-width:600px;margin-left:auto;margin-right:auto"> | | <img src="https://static.igem.org/mediawiki/2015/d/d4/Peking-Practice-Background-pic4.png" style="max-width:600px;margin-left:auto;margin-right:auto"> |
| + | </div> |
| + | <div class="col-md-2"></div> |
| + | </div> |
| <p class="text-center"><small><b>Figure 4. Estimated TB incidence rates in 2013 [4].</b><br/>The number of incident TB cases relative to the population size (the incidence rate) varies significantly among countries.</small></p> | | <p class="text-center"><small><b>Figure 4. Estimated TB incidence rates in 2013 [4].</b><br/>The number of incident TB cases relative to the population size (the incidence rate) varies significantly among countries.</small></p> |
| </div> | | </div> |
Line 253: |
Line 277: |
| | | |
| | | |
− | <h3 class="classic-title" style="margin-top:50px"><span>Part Ⅲ White plague in China</span></h3> | + | <h3 class="classic-title" style="margin-top:50px"><span>White plague in China</span></h3> |
| <div> | | <div> |
| <p>It was measured by WHO that near 1 million new TB cases were Chinese in 2013, accounting for 11% of the total number. In recent years, as the implementation of DOTS (Directly-Observed Treatment Strategy), the epidemic situation of TB has been controlled in China. However, it has been estimated that the amount of patients over 15 with active pulmonary TB is still huge, about 4.99 million. The morbidity is 45.9 per 1 million based on the 5th National Tuberculosis Epidemiological Survey in 2010 [5]. The good news was that the prevalence rate had decreased, but it just has a slower descending tendency in recent years (Figure 5). What’s worse, the absolute number of patients with active pulmonary TB estimated in 2010 had increased due to a great increase in the population size. </p> | | <p>It was measured by WHO that near 1 million new TB cases were Chinese in 2013, accounting for 11% of the total number. In recent years, as the implementation of DOTS (Directly-Observed Treatment Strategy), the epidemic situation of TB has been controlled in China. However, it has been estimated that the amount of patients over 15 with active pulmonary TB is still huge, about 4.99 million. The morbidity is 45.9 per 1 million based on the 5th National Tuberculosis Epidemiological Survey in 2010 [5]. The good news was that the prevalence rate had decreased, but it just has a slower descending tendency in recent years (Figure 5). What’s worse, the absolute number of patients with active pulmonary TB estimated in 2010 had increased due to a great increase in the population size. </p> |
− | <div class="col-md-12">
| + | <div> |
| + | <div class="row"> |
| + | <div class="col-md-2"></div> |
| + | <div class="col-md-7"> |
| + | |
| <img style="max-width:600px"src="https://static.igem.org/mediawiki/2015/d/de/Peking-Practice-Background-pic5.jpeg"> | | <img style="max-width:600px"src="https://static.igem.org/mediawiki/2015/d/de/Peking-Practice-Background-pic5.jpeg"> |
| + | </div> |
| + | <div class="col-md-3"></div> |
| + | </div> |
| <p class="text-center"><small><b>Figure 5. The trend of incidence population in China from 2008 to 2012.</b><br/></small></p> | | <p class="text-center"><small><b>Figure 5. The trend of incidence population in China from 2008 to 2012.</b><br/></small></p> |
| </div> | | </div> |
| <p> | | <p> |
− | As a high burden country, the epidemic situation of tuberculosis in China is severe and complicated, especially with the largest population in the world. The fact that 1/3 of the people are infected with Mycobacterium tuberculosis warns us that near 500 million people in China might be infected. Such an enormous population infected doubtlessly makes it difficult to fight against the disease. In addition, the regional development imbalance is another problem existing in our country. The prevalence in rural area is higher than in cities, while the western part is also significantly higher than the middle and eastern parts. Low educational level, poverty, remoteness and poor medical conditions make more people suffer from TB in the areas with higher morbidity. | + | As a high burden country, the epidemic situation of tuberculosis in China is severe and complicated, especially with the largest population in the world. The fact that 1/3 of the people are infected with <i>Mycobacterium tuberculosis</i> warns us that near 500 million people in China might be infected. Such an enormous population infected doubtlessly makes it difficult to fight against the disease. In addition, the regional development imbalance is another problem existing in our country. The prevalence in rural area is higher than in cities, while the western part is also significantly higher than the middle and eastern parts. Low educational level, poverty, remoteness and poor medical conditions make more people suffer from TB in the areas with higher morbidity. |
| </p> | | </p> |
| <p> | | <p> |
− | To ensure TB patients receive standard treatment, Chinese government requires all levels of medical organizations to transfer patients suspicious of or defined as TB to local tuberculosis dispensaries for proceeding unified examinations, treatments and managements. The government provides free primary examination items and antitubercular agents for infectious pulmonary tuberculosis patients. These items include [6]: </p> | + | To ensure TB patients receive standard treatment, Chinese government requires all levels of medical organizations to transfer patients suspicious of or defined as TB to local tuberculosis dispensaries for proceeding unified examinations, treatments and managements. The government provides free primary examination items and antitubercular agents for infectious pulmonary tuberculosis patients. These items include[6]: </p> |
| <div> | | <div> |
| <ol style="color:#666"> | | <ol style="color:#666"> |
Line 275: |
Line 306: |
| | | |
| | | |
− | <h3 class="classic-title" style="margin-top:50px"><span>Part Ⅳ The diagnosis and prognosis of TB</span></h3> | + | <h3 class="classic-title" style="margin-top:50px"><span>The diagnosis and prognosis of TB</span></h3> |
| <div> | | <div> |
| <p>Pulmonary tuberculosis is not a kind of fatal illness any more thanks to the chemotherapeutics such as Rifampicin, Isoniazid and Ethambutol. If the therapeutic regimen for TB, which is a long course of taking medicine without any interruption, is strictly followed, pulmonary TB is curable with a high recovery rate of over 85%. Thus, early detection is core for TB control since the disease has a high recovery rate. Studies have demonstrated that there is a significant difference between the delayed treatment group and the early therapy group both in the severity and prognosis of the disease [7].</p> | | <p>Pulmonary tuberculosis is not a kind of fatal illness any more thanks to the chemotherapeutics such as Rifampicin, Isoniazid and Ethambutol. If the therapeutic regimen for TB, which is a long course of taking medicine without any interruption, is strictly followed, pulmonary TB is curable with a high recovery rate of over 85%. Thus, early detection is core for TB control since the disease has a high recovery rate. Studies have demonstrated that there is a significant difference between the delayed treatment group and the early therapy group both in the severity and prognosis of the disease [7].</p> |
| <p>Delayed treatment has various degrees of impact on the prognosis of TB patients. Pulmonary tuberculosis cases, accompanied by tuberculous pleuritic, are more common among patients with delayed treatment. The chest radiography has prompted that there is more chance to attain multi-lobar lesions and extra pulmonary tuberculosis for patients with delayed treatment. <i>Mycobacterium tuberculosis</i> in active state will proliferate in patients’ lung tissue to form a nidus before the patients receive any treatment. Congestion, exudation, edema and phagocytosis can be seen in the injured tissues. It will keep on developing hyperplastic nodules in lungs composed of collective lymphocytes, or caseous necrosis with the bacteria and necrotic tissues. Both conditions will stimulate the body to produce fibroblasts, and proceed to the next step of fibrosis, which make the antitubercular agents difficult to infiltrate into the injured tissues. Thus the possibility of failure on chemotherapeutics in short course greatly increases in these cases. On the other hand, if the bacteria in the caseous necrosis multiply rapidly, tissues would often form thick cavities with liquefactive necrosis. Once fibrosis of the cavity wall occurs, the number of blood vessels will greatly decrease, therefore leading to a low concentration of the antitubercular agents in the affected tissues if drugs are administered orally or by intravenous injection. </p> | | <p>Delayed treatment has various degrees of impact on the prognosis of TB patients. Pulmonary tuberculosis cases, accompanied by tuberculous pleuritic, are more common among patients with delayed treatment. The chest radiography has prompted that there is more chance to attain multi-lobar lesions and extra pulmonary tuberculosis for patients with delayed treatment. <i>Mycobacterium tuberculosis</i> in active state will proliferate in patients’ lung tissue to form a nidus before the patients receive any treatment. Congestion, exudation, edema and phagocytosis can be seen in the injured tissues. It will keep on developing hyperplastic nodules in lungs composed of collective lymphocytes, or caseous necrosis with the bacteria and necrotic tissues. Both conditions will stimulate the body to produce fibroblasts, and proceed to the next step of fibrosis, which make the antitubercular agents difficult to infiltrate into the injured tissues. Thus the possibility of failure on chemotherapeutics in short course greatly increases in these cases. On the other hand, if the bacteria in the caseous necrosis multiply rapidly, tissues would often form thick cavities with liquefactive necrosis. Once fibrosis of the cavity wall occurs, the number of blood vessels will greatly decrease, therefore leading to a low concentration of the antitubercular agents in the affected tissues if drugs are administered orally or by intravenous injection. </p> |
| + | |
| <div class="col-md-9"> | | <div class="col-md-9"> |
| <img src="https://static.igem.org/mediawiki/2015/4/41/Peking-Practice-Background-pic6.jpg" class="col-md-12"> | | <img src="https://static.igem.org/mediawiki/2015/4/41/Peking-Practice-Background-pic6.jpg" class="col-md-12"> |
− | <p class="text-center"><small><b>Figure 6. Tubercular nodule in the lung tissue in the microscopic view. </b><br/><b>(A)</b> Caseous necrosis in the center of the tubercle contains a huge number of Mycobacterium tuberculosis.<b> <br/>(B)</b> Mononuclear phagocytes and lymphocytes surrounding the caseous necrosis.</small></p> | + | <p><small><b>Figure 6. Tubercular nodule in the lung tissue in the microscopic view. </b><b>(A)</b> Caseous necrosis in the center of the tubercle contains a huge number of <i>Mycobacterium tuberculosis</i>. <b>(B)</b> Mononuclear phagocytes and lymphocytes surrounding the caseous necrosis.</small></p> |
| </div> | | </div> |
| <p>The most serious condition is that a small portion of patients will not be sensitive to antitubercular agents due to delayed treatment, and it may develop chronic fibro-cavitary pulmonary tuberculosis, which may never be cured. Chronic fibro-cavitary pulmonary tuberculosis will destroy normal tissues in lungs. Even if the bacteria are sensitive to the agents, the lung tissue can never return to normal state with a permanent deficiency of the pulmonary functions.</p> | | <p>The most serious condition is that a small portion of patients will not be sensitive to antitubercular agents due to delayed treatment, and it may develop chronic fibro-cavitary pulmonary tuberculosis, which may never be cured. Chronic fibro-cavitary pulmonary tuberculosis will destroy normal tissues in lungs. Even if the bacteria are sensitive to the agents, the lung tissue can never return to normal state with a permanent deficiency of the pulmonary functions.</p> |
Line 288: |
Line 320: |
| | | |
| | | |
− | <h3 class="classic-title" style="margin-top:50px"><span>Part Ⅴ 2015, a crucial year for TB control</span></h3> | + | <h3 class="classic-title" style="margin-top:50px"><span>2015, a crucial year for TB control</span></h3> |
| <div> | | <div> |
| <div style="margin-top:40px"> | | <div style="margin-top:40px"> |
Line 349: |
Line 381: |
| <div> | | <div> |
| <ol > | | <ol > |
− | <li><a href="http://www.webmd.com/lung-cancer/x-ray-of-a-normal-chest">http://www.webmd.com/lung-cancer/x-ray-of-a-normal-chest</a></li> | + | <li style="color:#6060;"><a href="http://www.webmd.com/lung-cancer/x-ray-of-a-normal-chest">http://www.webmd.com/lung-cancer/x-ray-of-a-normal-chest</a></li> |
− | <li><a href="http://www.physio-pedia.com/Tuberculosis">http://www.physio-pedia.com/Tuberculosis</a></li> | + | <li style="color:#6060;"><a href="http://www.physio-pedia.com/Tuberculosis">http://www.physio-pedia.com/Tuberculosis</a></li> |
− | <li><a href="http://radiopaedia.org/cases/cavitating-pulmonary-tuberculosis-gross-pathology-1">http://radiopaedia.org/cases/cavitating-pulmonary-tuberculosis-gross-pathology-1</a></li> | + | <li style="color:#6060;"><a href="http://radiopaedia.org/cases/cavitating-pulmonary-tuberculosis-gross-pathology-1">http://radiopaedia.org/cases/cavitating-pulmonary-tuberculosis-gross-pathology-1</a></li> |
| <li>WHO. Global Tuberculosis Report 2014[M]. World Health Organization, 2014.</li> | | <li>WHO. Global Tuberculosis Report 2014[M]. World Health Organization, 2014.</li> |
| <li>Wang L X, Cheng S M, Chen M T, et al. The fifth national tuberculosis epidemiological survey in 2010[J]. Chinese Journal of Antituberculosis, 2012, 34: 485-508.</li> | | <li>Wang L X, Cheng S M, Chen M T, et al. The fifth national tuberculosis epidemiological survey in 2010[J]. Chinese Journal of Antituberculosis, 2012, 34: 485-508.</li> |
− | <li><a href="http://www.bjjks.org/?action-viewnews-itemid-312">http://www.bjjks.org/?action-viewnews-itemid-312</a></li> | + | <li style="color:#6060;"><a href="http://www.bjjks.org/?action-viewnews-itemid-312">http://www.bjjks.org/?action-viewnews-itemid-312</a></li> |
| <li> CUI Ping, YANG Zhi-hong, CHENG Cong. Study on patient delay and prognosis in the youth patients with pulmonary tuberculosis[J]. Guide of China Medicine, 2012, 33: 33-35.</li> | | <li> CUI Ping, YANG Zhi-hong, CHENG Cong. Study on patient delay and prognosis in the youth patients with pulmonary tuberculosis[J]. Guide of China Medicine, 2012, 33: 33-35.</li> |
| </ol> | | </ol> |
Line 378: |
Line 410: |
| <ul class="social-icons" style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0"> | | <ul class="social-icons" style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0"> |
| <li style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0"><!--HERE need to be changed--> | | <li style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0"><!--HERE need to be changed--> |
− | <a class="twitter" target="_blank" href="https://twitter.com/home/?status=https://2015.igem.org/Team:Peking/Practices/Background"> | + | <a class="twitter" target="_blank" href="https://twitter.com/home/?status=https://2015.igem.org/Team:Peking"> |
| <i class="fa"> | | <i class="fa"> |
| <img src="https://static.igem.org/mediawiki/2015/d/d0/Peking-twitter.png" style="height:20px;width:auto; margin-top:7px;"> | | <img src="https://static.igem.org/mediawiki/2015/d/d0/Peking-twitter.png" style="height:20px;width:auto; margin-top:7px;"> |
Line 385: |
Line 417: |
| </li> | | </li> |
| <li style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0"><!--HERE need to be changed--> | | <li style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0"><!--HERE need to be changed--> |
− | <a class="facebook"target="_blank" href="https://www.facebook.com/sharer/sharer.php?u=https://2015.igem.org/Team:Peking/Practices/Background"> | + | <a class="facebook"target="_blank" href="https://www.facebook.com/sharer/sharer.php?u=https://2015.igem.org/Team:Peking"> |
| <i class="fa"> | | <i class="fa"> |
| <img src="https://static.igem.org/mediawiki/2015/0/0e/Peking-facebook.png" style="height:20px; margin-top:7px;"> | | <img src="https://static.igem.org/mediawiki/2015/0/0e/Peking-facebook.png" style="height:20px; margin-top:7px;"> |
Line 392: |
Line 424: |
| </li> | | </li> |
| <li style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0"><!--HERE need to be changed--> | | <li style="padding-top:0:padding-bottom:0;margin-top:0;margin-bottom:0"><!--HERE need to be changed--> |
− | <a class="google"target="_blank" href="https://plus.google.com/share?url=https://2015.igem.org/Team:Peking/Practices/Background"> | + | <a class="google"target="_blank" href="https://plus.google.com/share?url=https://2015.igem.org/Team:Peking"> |
| <i class="fa"> | | <i class="fa"> |
| <img src="https://static.igem.org/mediawiki/2015/7/7a/Peking-google_plus.png" style="height:20px; margin-top:7px;"> | | <img src="https://static.igem.org/mediawiki/2015/7/7a/Peking-google_plus.png" style="height:20px; margin-top:7px;"> |
Line 485: |
Line 517: |
| | | |
| <!-- Go To Top Link --> | | <!-- Go To Top Link --> |
− | <a href="#" class="back-to-top" style="z-index:9999"><i class="fa"><img src="https://static.igem.org/mediawiki/2015/0/06/Peking-Up.png" style="margin-top:2px; width:90%"></i></a> | + | <a href="#" class="back-to-top" style="z-index:9999"><i class="fa"><img src="https://static.igem.org/mediawiki/2015/0/06/Peking-Up.png" style=" width:90%"></i></a> |
| | | |
| <div id="loader"> | | <div id="loader"> |